Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Diabetic Macular Edema · Hypercholesterolemia · REGN

Regeneron UK

Regeneron UK Limited

Regeneron UK clinical programs — 493 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Tarrytown, USA HQ
16,715 Employees
Public company Type
REGN · NYSE Ticker
Company details
Status
Public
HQ
Tarrytown, USA
Employees
16,715
Programs
493
Drugs
98
Patents
837
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Regeneron UK projects

493 ClinicalTrials.gov programs sponsored by Regeneron UK.

Regeneron UK has 493 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

493 programs

Clinical programs

Page 4 of 11

  1. Aspirin Challenge

    Regeneron UK Limited

    Aspirin-exacerbated Respiratory Disease

    phase 2 small molecule completed

    1 trial

  2. BNT111

    Regeneron UK Limited

    Melanoma Stage III

    phase 2 mab completed

    1 trial

  3. BNT116

    Regeneron UK Limited

    Advanced Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  4. CMP-001

    Regeneron UK Limited

    Squamous Cell Carcinoma of Head and Neck

    phase 2 small molecule terminated

    1 trial

  5. Capecitabine

    Regeneron UK Limited

    Colorectal Cancer Metastatic

    phase 2 small molecule terminated

    1 trial

  6. Cemiplimab

    Regeneron UK Limited

    Pleural Mesotheliomas

    phase 2 small molecule active

    1 trial

  7. Cemiplimab

    Regeneron UK Limited

    High-Grade Glioma (HGG)

    phase 2 small molecule active

    1 trial

  8. Cemiplimab

    Regeneron UK Limited

    Locally Recurrent Oral Cavity Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  9. Cemiplimab

    Regeneron UK Limited

    Locally Advanced Basal Cell Carcinoma

    phase 2 mab active

    1 trial

  10. Cemiplimab

    Regeneron UK Limited

    HPV-Related Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  11. Cemiplimab

    Regeneron UK Limited

    Hodgkin Lymphoma

    phase 2 small molecule terminated

    1 trial

  12. Cemiplimab

    Regeneron UK Limited

    Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  13. Cemiplimab

    Regeneron UK Limited

    Hepatitis B Virus

    phase 2 mab terminated

    1 trial

  14. Cemiplimab

    Regeneron UK Limited

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  15. Cemiplimab

    Regeneron UK Limited

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  16. Cemiplimab

    Regeneron UK Limited

    Colon Cancer

    phase 2 small molecule active

    1 trial

  17. Cemiplimab

    Regeneron UK Limited

    Colon and Rectal Cancer

    phase 2 small molecule active

    1 trial

  18. Cemiplimab

    Regeneron UK Limited

    Colo-rectal Cancer

    phase 2 small molecule active

    1 trial

  19. Cemiplimab

    Regeneron UK Limited

    Cervical Cancer

    phase 2 small molecule completed

    1 trial

  20. Cemiplimab

    Regeneron UK Limited

    Bladder Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  21. Cemiplimab

    Regeneron UK Limited

    Basal Cell Carcinoma (BCC)

    phase 2 small molecule active

    1 trial

  22. Cemiplimab

    Regeneron UK Limited

    Metastatic Solid Tumor

    phase 2 small molecule active

    1 trial

  23. Cemiplimab

    Regeneron UK Limited

    HIV Infections

    phase 2 mab terminated

    1 trial

  24. Cemiplimab

    Regeneron UK Limited

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule active

    1 trial

  25. Cemiplimab

    Regeneron UK Limited

    NSCLC

    phase 2 small molecule active

    1 trial

  26. Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]

    Regeneron UK Limited

    Colon Cancer

    phase 2 small molecule active

    1 trial

  27. Cemiplimab 350 MG Intravenous Solution

    Regeneron UK Limited

    Clear Cell Renal Cell Carcinoma

    phase 2 small molecule active

    1 trial

  28. Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles

    Regeneron UK Limited

    Merkel Cell Carcinoma, Stage I

    phase 2 small molecule active

    1 trial

  29. Cemiplimab Plus Gemcitabine

    Regeneron UK Limited

    Pancreatic Ductal Adenocarcinoma (mPDAC)

    phase 2 small molecule active

    1 trial

  30. Cemiplimab-Rwlc

    Regeneron UK Limited

    Non-small Cell Lung Cancer Stage III

    phase 2 small molecule active

    1 trial

  31. Cemiplimab-Rwlc

    Regeneron UK Limited

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule terminated

    1 trial

  32. Cemiplimab-Rwlc

    Regeneron UK Limited

    Cutaneous Squamous Cell Carcinoma

    phase 2 small molecule terminated

    2 trials

  33. DB-OTO

    Regeneron UK Limited

    Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)

    phase 2 gene therapy active

    1 trial

  34. Degarelix

    Regeneron UK Limited

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  35. Dupilumab

    Regeneron UK Limited

    Peanut Allergy

    phase 2 small molecule completed

    2 trials

  36. Dupilumab

    Regeneron UK Limited

    Atopic Keratoconjunctivitis

    phase 2 small molecule active

    1 trial

  37. Dupilumab

    Regeneron UK Limited

    Colitis Ulcerative

    phase 2 small molecule active

    1 trial

  38. Dupilumab

    Regeneron UK Limited

    Alopecia Areata

    phase 2 small molecule active

    2 trials

  39. Dupilumab

    Regeneron UK Limited

    Asthma, Allergic

    phase 2 small molecule active

    1 trial

  40. Dupilumab

    Regeneron UK Limited

    Allergies Food Milk

    phase 2 small molecule terminated

    1 trial

  41. Dupilumab

    Regeneron UK Limited

    Eosinophilic Gastritis (EoG)

    phase 2 small molecule active

    1 trial

  42. Dupilumab

    Regeneron UK Limited

    Pruritis

    phase 2 small molecule active

    1 trial

  43. Dupilumab

    Regeneron UK Limited

    Prostate Cancer

    phase 2 small molecule terminated

    1 trial

  44. Dupilumab

    Regeneron UK Limited

    Allergic Rhinitis

    phase 2 small molecule completed

    1 trial

  45. Dupilumab (blinded)

    Regeneron UK Limited

    Eosinophilic Gastritis

    phase 2 small molecule completed

    1 trial

  46. Dupilumab 300Mg Solution for Injection

    Regeneron UK Limited

    Pruritus

    phase 2 small molecule completed

    1 trial

  47. Dupixent®

    Regeneron UK Limited

    Allergic Rhinoconjunctivitis

    phase 2 mab completed

    1 trial

  48. Encorafenib + Binimetinib

    Regeneron UK Limited

    Melanoma BRAF V600E/K Mutated

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Regeneron UK have?

493 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.